DERMAVUE SUPERHUMAN · GOLD STANDARD
Mounjaro (Tirzepatide): The Most Effective Weight Loss Medication Available
The First Dual-Action GIP/GLP-1 Medication — Up to 22% Weight Loss in Clinical Trials
DermaVue First-Line Choice · Book a Consultation
UNDERSTANDING THE MEDICATION
What is Mounjaro? Understanding Tirzepatide
Mounjaro (tirzepatide) is a once-weekly injectable medication manufactured by Eli Lilly that represents a breakthrough in obesity medicine. It is the first and only medication that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors simultaneously — a dual mechanism that produces significantly greater weight loss than any single-receptor medication available today.
In the landmark SURMOUNT-1 trial published in the New England Journal of Medicine (2022), tirzepatide at the 15 mg dose achieved an average weight loss of 22.5% over 72 weeks — the highest weight loss ever recorded for a non-surgical treatment. DermaVue prescribes Mounjaro as the first-line medication in our dermatologist-led SuperHuman Program, with structured dosing, skin protection, and body composition monitoring across all 7 clinics in Kerala and Tamil Nadu.
| Brand Name | Mounjaro (weight management: Zepbound) |
|---|---|
| Generic Name | Tirzepatide |
| Manufacturer | Eli Lilly and Company |
| Drug Class | Dual GIP/GLP-1 Receptor Agonist |
| Administration | Once-weekly subcutaneous injection (pre-filled pen) |
| Available Doses | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg |
| Key Trial | SURMOUNT-1: up to 22.5% weight loss over 72 weeks |
| DermaVue Status | First-line recommendation (Gold Standard) |
DUAL MECHANISM OF ACTION
How Tirzepatide's Dual GIP/GLP-1 Action Works
Unlike Ozempic (semaglutide) which activates only the GLP-1 receptor, Mounjaro simultaneously activates two receptors — producing synergistic effects that no single-receptor drug can match.
GLP-1 Pathway
Shared with Ozempic- Reduces appetite via hypothalamic signaling
- Slows gastric emptying (delays food leaving stomach)
- Stimulates glucose-dependent insulin secretion
- Suppresses glucagon release (reduces liver glucose output)
- Improves satiety and reduces food intake
GIP Pathway
Unique to Mounjaro- Enhances insulin sensitivity in adipose tissue
- Improves fat metabolism and lipid handling
- Reduces fat storage in visceral depots
- Boosts energy expenditure (thermogenesis)
- Synergizes with GLP-1 for amplified weight loss
Combined Effects on the Body
| Target Organ | GLP-1 Effect | GIP Effect (Mounjaro Only) |
|---|---|---|
| Brain | Reduces hunger signals, increases satiety | Enhances reward-center modulation |
| Stomach | Slows gastric emptying | Complementary motility regulation |
| Pancreas | Increases insulin, decreases glucagon | Further insulin sensitization |
| Fat Tissue | Modest lipolysis | Enhanced fat oxidation, reduced lipogenesis |
| Liver | Reduced glucose output | Improved lipid metabolism, reduced steatosis |
| Metabolism | Moderate caloric deficit | Increased energy expenditure (thermogenesis) |
CLINICAL EVIDENCE
What Clinical Trials Show: The SURMOUNT-1 Data
Tirzepatide has the strongest evidence base of any weight loss medication ever studied. Two landmark trials define its superiority.
SURMOUNT-1 Trial (New England Journal of Medicine, 2022)
Randomized, double-blind, placebo-controlled · 2,539 participants · 72 weeks · NCT04184622
Tirzepatide 5 mg
-16.0%
Mean body weight reduction
Tirzepatide 10 mg
-21.4%
Mean body weight reduction
Tirzepatide 15 mg
-22.5%
Mean body weight reduction
Placebo group: -2.4% · All results statistically significant (p<0.001)
SURMOUNT-5 Head-to-Head Trial (NCT05822778)
Tirzepatide: -20.2% vs Semaglutide: -13.7%
47% more weight loss with Mounjaro vs Ozempic · 72 weeks · Open-label, head-to-head
STRUCTURED TITRATION
DermaVue's Mounjaro Dosing Protocol
Every patient follows a structured dose escalation schedule. Your doctor adjusts the pace based on tolerability and response.
| Phase | Weeks | Dose | Purpose |
|---|---|---|---|
| Initiation | 1–4 | 2.5 mg | GI tolerance building (not a therapeutic dose) |
| First therapeutic | 5–8 | 5.0 mg | First effective weight loss dose |
| Escalation 1 | 9–12 | 7.5 mg | Increased receptor activation |
| Escalation 2 | 13–16 | 10 mg | Strong weight loss response |
| Escalation 3 | 17–20 | 12.5 mg | Near-maximum response |
| Maximum | 21+ | 15 mg | Maximum dose (if needed) |
Not all patients need the maximum dose. Many achieve their target weight at 7.5–10 mg. Your DermaVue doctor adjusts based on weight loss trajectory, side effect profile, and metabolic markers.
IDEAL CANDIDATES
Who Should Use Mounjaro at DermaVue?
Mounjaro is DermaVue's first-line recommendation. It is particularly effective for patients with the following profiles:
BMI > 27 with Comorbidities
Overweight or obese patients (Indian cutoff BMI ≥23 with risk factors, or BMI ≥27) seeking significant, sustained weight loss.
High Insulin Resistance (HOMA-IR > 2.5)
Tirzepatide's dual mechanism directly targets insulin resistance — the GIP pathway improves adipose tissue insulin sensitivity.
Type 2 Diabetes / Prediabetes
Originally developed as a diabetes medication (HbA1c reduction of ~2.1%). Treats weight and blood sugar simultaneously.
PCOS (Polycystic Ovary Syndrome)
Improves the insulin resistance that drives PCOS — reduces androgen levels, restores menstrual regularity, aids fertility.
NAFLD / Fatty Liver
The GIP pathway improves hepatic lipid metabolism. SURMOUNT data shows significant reduction in liver fat content.
Metabolic Syndrome
Central obesity + hypertension + dyslipidemia + insulin resistance — tirzepatide improves all four components simultaneously.
Previous Semaglutide Failure
Patients who plateaued on Ozempic/Wegovy often achieve renewed weight loss when switching to the dual-receptor Mounjaro.
PCOS & INSULIN RESISTANCE
Mounjaro for PCOS Weight Loss in India
Polycystic Ovary Syndrome (PCOS) affects up to 20% of Indian women of reproductive age. The metabolic root of PCOS is insulin resistance — elevated insulin drives the ovaries to produce excess androgens (testosterone), causing irregular periods, acne, hirsutism, and weight gain (particularly visceral/belly fat).
Tirzepatide's dual GIP/GLP-1 mechanism is uniquely suited for PCOS because the GIP receptor directly improves insulin sensitivity in adipose tissue — addressing the root metabolic driver. By reducing insulin resistance, androgen production falls, leading to improvements in menstrual regularity, skin symptoms, and fertility.
Meta-Analysis Evidence: GLP-1 receptor agonists in PCOS demonstrate significant reductions in BMI (−2.20 kg/m²), waist circumference, fasting insulin, HOMA-IR, and total testosterone levels. The addition of the GIP pathway in tirzepatide is expected to amplify these benefits — clinical trials in PCOS-specific populations are ongoing (SURMOUNT-PCOS).
HEAD-TO-HEAD COMPARISON
Mounjaro vs Ozempic: The Honest Comparison
Both are excellent medications. But the data clearly shows tirzepatide's dual mechanism delivers superior results for most patients.
| Factor | Mounjaro (Tirzepatide) | Ozempic (Semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist only |
| Weight Loss (trial) | Up to 22.5% (SURMOUNT-1, 15 mg) | Up to 14.9% (STEP 1, 2.4 mg) |
| Head-to-Head (SURMOUNT-5) | -20.2% body weight | -13.7% body weight |
| Best For | Insulin resistance, T2D, PCOS, NAFLD, maximum weight loss | Moderate weight loss, cardiovascular risk reduction |
| GI Side Effects | Similar frequency, often milder with slower titration | Similar frequency |
| India Availability | Widely available | Widely available (branded + generic) |
| DermaVue Recommendation | First-line (Gold Standard) | Alternative for specific clinical indications |
DermaVue's Position: We recommend Mounjaro (tirzepatide) as first-line for most patients in our SuperHuman Program. The dual mechanism produces 47% more weight loss than semaglutide in head-to-head data, with particular advantages for patients with insulin resistance, PCOS, and fatty liver. Ozempic remains an excellent option for patients with specific clinical indications or the thin-fat phenotype.
SAFETY & TOLERABILITY
Mounjaro Side Effects & Management
Most side effects are gastrointestinal, mild-to-moderate, and resolve within 2–4 weeks at each dose level. DermaVue provides proactive management protocols.
| Side Effect | Frequency | DermaVue Management |
|---|---|---|
| Nausea | ~25% (usually mild, weeks 1–3 at each dose) | Eat smaller meals, avoid high-fat food before injection, ginger supplements, ondansetron if needed |
| Diarrhea | ~15% | Hydration, probiotics, dose hold if persistent |
| Constipation | ~10% | Fiber supplementation, adequate water (2.5–3L/day), magnesium citrate |
| Decreased Appetite | ~20% (therapeutic effect) | Protein-first eating strategy to prevent muscle loss; minimum 1.2 g/kg protein daily |
| Injection Site Reaction | ~5% | Rotate injection sites (abdomen, thigh, upper arm) |
MOUNJARO AVAILABILITY
Mounjaro (Tirzepatide) Availability in India
Mounjaro is available at all 7 DermaVue clinics. Dosing and medication options are discussed during your consultation with the doctor.
Medication pricing varies by type and dose. Your doctor will discuss options during your consultation. DermaVue does not sell medications directly — prescriptions are provided after clinical evaluation and medications are purchased from licensed pharmacies.
FREQUENTLY ASKED QUESTIONS
Mounjaro Tirzepatide FAQ
-
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication that activates both GIP and GLP-1 receptors. It is the first dual-action incretin medication approved for weight management and type 2 diabetes, manufactured by Eli Lilly.
-
Tirzepatide activates two gut hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This dual mechanism reduces appetite, slows gastric emptying, improves insulin sensitivity, enhances fat metabolism, and increases energy expenditure — producing significantly greater weight loss than single-receptor GLP-1 drugs.
-
In the SURMOUNT-1 clinical trial, participants lost an average of 22.5% of body weight on the 15 mg dose over 72 weeks. Results vary individually. The SURMOUNT-5 head-to-head trial showed tirzepatide produced 47% more weight loss than semaglutide (20.2% vs 13.7%).
-
DermaVue follows a structured titration: 2.5 mg for weeks 1–4, then 5 mg (weeks 5–8), 7.5 mg (weeks 9–12), 10 mg (weeks 13–16), 12.5 mg (weeks 17–20), and 15 mg from week 21 onward. Not all patients require the maximum dose — your doctor adjusts based on response and tolerability.
-
The most common side effects are gastrointestinal: nausea (affecting ~25% of patients, usually mild and transient), diarrhea, constipation, and decreased appetite. Most side effects improve within 2–4 weeks at each dose level. DermaVue provides anti-nausea protocols to minimize discomfort.
-
Yes, Mounjaro (tirzepatide) is available at all 7 DermaVue locations across Kerala and Tamil Nadu. Your doctor will determine the appropriate starting dose based on your health profile, and the medication is sourced through authorized pharmaceutical channels.
-
Yes. Tirzepatide’s dual GIP/GLP-1 mechanism is particularly effective for PCOS because it directly improves insulin resistance — the metabolic driver of PCOS. Meta-analyses show GLP-1 agonists significantly reduce BMI, waist circumference, and testosterone levels in PCOS patients.
-
Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should not be used during pregnancy or breastfeeding. Patients with a history of pancreatitis require careful evaluation. A doctor assessment at DermaVue determines eligibility.
DERMAVUE SUPERHUMAN PROGRAM
Ready to Start Your SuperHuman Journey?
Talk to a doctor — free 10-minute WhatsApp consultation
★ 4.8 rating · 7,200+ patients · Dermatologist-led program
